Leica Biosystems, a global leader in anatomic pathology laboratory solutions and instruments, announced today that it has successfully completed its previously announced acquisition of Devicor Medical Products.
Devicor is a global market leader in breast biopsy instruments and consumables, with annual revenues of approximately $170 million.
It is committed to advancing technology to help clinicians accurately diagnose breast disease, such as breast cancer, through minimally invasive procedures. Among Devicor’s products is the Original Mammotome Breast Biopsy System, which, to date, has enabled more than four million women to have a minimally invasive breast biopsy.
"Leica’s Biosystems’ products and solutions address the key steps across the anatomic pathology laboratory workflow. The addition of Devicor’s market leading breast biopsy products, especially Mammotome, allows us to further integrate that workflow from the source, starting with the patient and the biopsy sample," said Matthias Weber, MD, President of Leica Biosystems.
"This acquisition supports our mission of advancing cancer diagnostics to improve lives by adding products that will have direct benefits for the patients and the clinicians who care for them."
Devicor will operate as a standalone business within Leica Biosystems and will continue to be led by Tom Daulton, the current CEO of Devicor. No other financial terms and conditions have been disclosed.